エピソード

  • JNJ Today - Aug 13: Tiny Move, Big Questions

    JNJ Today - Aug 13: Tiny Move, Big Questions
    2026/08/13
    Hey there! I'm Joey, a longtime investor just breaking down how Johnson & Johnson did today. So, JNJ had a pretty chill day. It barely moved, just up a tiny bit—like, 0.04%. Not exactly fireworks, right?

    So, what happened? Honestly, not much. The stock just kind of floated around. Volume was right on average, so no big rush in either direction. It seems like everyone’s just waiting to see what’s next.

    Now, why is that? Well, a couple of things are buzzing around. There’s some chatter about JNJ hitting that massive $100 billion revenue mark soon. That's a big deal! But then there’s also talk about some firms selling off shares, like Guardian Investment Management unloading almost 9,000 shares. That kind of stuff can make people a bit jittery. Plus, there's a comparison with AbbVie floating around, where people are weighing JNJ's safe dividend against AbbVie’s higher yield. It’s like a stock showdown, and folks are trying to figure out which is the better bet.

    Oh, and JNJ is creeping up to a 52-week high. So, that’s got some folks curious—are we in for a climb, or is it just a tease?

    Just a little heads up: some firms are boosting their stakes in JNJ, which might mean they see something good coming down the line.

    So, yeah, that’s the scoop for today. A lot of uncertainty, but that’s stock life for ya! Remember, this is just info to keep you in the loop, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • JNJ Today - Aug 12: Stock Stays Flat Amid Buzz

    JNJ Today - Aug 12: Stock Stays Flat Amid Buzz
    2026/08/12
    Hey there! It’s Joey here, your friendly longtime investor breaking down the day for you. Today, we’re talking about Johnson & Johnson, and it was kind of a flat day for the stock. It barely moved, just a slight dip of 0.07%. Not much to write home about!

    So, what went down? JNJ opened up and then just sorta hung around. No big swings, no crazy drama. It’s like that friend who shows up to the party but just stands by the snack table. The volume was right on point with its average, so people were trading like usual, but nobody was making any wild moves.

    Now, why did JNJ stay so chill? Well, there’s a lot of chatter about the company hitting that massive $100 billion revenue mark soon, which is super exciting! But with all that buzz, folks are still debating whether the stock is worth grabbing right now. Some articles even mention it's nearing a 52-week high, which can make investors think twice before diving in. Plus, there’s news about JNJ advancing its Seltorexant treatment for major depressive disorder, which is a big deal. But again, no one really knows what that means for the stock today.

    One thing worth noting is that Annex Advisory Services sold over 5,000 shares. That’s a decent chunk, and it could make some investors raise an eyebrow. It’s always interesting when you see big players making moves.

    So, yeah, the stock kinda just sat there today. JNJ’s got some exciting stuff on the horizon, but today was just a slow bleed. As always, just remember this is all for fun and info, not advice. Catch you later!
    続きを読む 一部表示
    1 分
  • JNJ Today - Aug 11: Insider Selling Sparks Concern

    JNJ Today - Aug 11: Insider Selling Sparks Concern
    2026/08/11
    Hey there! It's Joey, your friendly investor buddy, and I've been around the block a few times when it comes to stocks. Today, we're talking about Johnson & Johnson, and it was a bit of a red day, dropping by about three-quarters of a percent.

    So, what happened? Well, JNJ got smoked a little, losing a couple bucks off its price. Not a huge move, but enough to catch some eyes. The trading volume was right on average, so it wasn't like everyone was panicking or anything.

    Now, let’s chat about why it dropped. There’s been some buzz lately about insider selling. Yeah, that one stung. When insiders sell their shares, it can make people wonder if they know something we don’t. Plus, there's chatter about JNJ’s position compared to other healthcare stocks, like Medtronic. Some analysts are weighing in on which stock is better post-earnings, and that can shake things up.

    There’s also a healthcare conference coming up on September 14th where JNJ’s gonna be chatting. Investors are probably keeping an eye on that because it could give some hints about what’s next for the company.

    To wrap it up, JNJ had a tough day with some insider selling raising eyebrows and competition in the healthcare space heating up. But hey, that’s how it goes in the market! Just remember, this is all for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • JNJ Today - Aug 10: Insider Sells Shares

    JNJ Today - Aug 10: Insider Sells Shares
    2026/08/10
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we're talking about Johnson & Johnson. Spoiler alert: it was a pretty chill day for JNJ, barely moving at all, just a tiny uptick of 0.1%.

    So, here’s the scoop. JNJ closed the day at 259.5, which is basically where it started. No big swings, just a slow day in the market. You know how sometimes stocks just kind of...exist? That was JNJ today.

    Now, why was it so quiet? Well, some chatter got stirred up because an insider sold off some shares. Yeah, that one stung a bit. When insiders sell, it sometimes makes people a little jittery, wondering if they know something we don’t. But honestly, it might just be a personal financial move. Who knows?

    On the flip side, there was some good news too. Johnson & Johnson signed a multiyear deal with ACCESS GPO for cardiac stuff in ambulatory surgery centers. That sounds all fancy and important, right? Basically, it means they’re expanding their reach in the healthcare space, which is a solid move. But still, it didn’t seem to get the stock buzzing today.

    And there’s a bit of noise in the market too. Some folks are questioning if JNJ might be overvalued based on certain analyses. It’s always a mixed bag with big companies like this. They’ve got a solid history, especially with that sweet dividend they’ve been pumping out for 64 years straight. Investors love that steady income, but it doesn’t always translate to stock price action.

    One more thing to keep an eye on: the healthcare sector is getting a lot of attention right now, with some analysts pointing out other beaten-down stocks that might be worth a look. JNJ is part of that discussion, but again, it’s just chatter for now.

    So, that’s the lowdown on JNJ today. Just a chill day with some ups and downs in the news. Remember, I’m just here to share what’s happening, not to give financial advice. Keep doing your own research and stay savvy out there! Catch you later!
    続きを読む 一部表示
    2 分
  • JNJ Today - Aug 09: Insider Selling Raises Eyebrows

    JNJ Today - Aug 09: Insider Selling Raises Eyebrows
    2026/08/09
    Hey there! It's Joey, your friendly neighborhood investor, here to break down what went down with Johnson & Johnson today. So, JNJ had a pretty chill day, up just about 0.88%. Not a huge jump, but hey, it’s still in the green!

    So, what’s the deal? JNJ’s stock kinda cruised along today. Volume was steady, and honestly, it didn’t do much to shake things up. Just a slow day without any wild swings. But here's the kicker: there was some big insider selling happening. Yeah, one of the big shots at the company sold over $12 million worth of stock. That usually raises some eyebrows, you know? People start wondering if they know something we don’t.

    Now, why did it move? Well, some articles pointed out that while JNJ looks cheap based on cash flow, it might be pricey when you look at earnings. That’s a mixed bag, right? Plus, the company has a solid history—64 years of increasing dividends. If you throw down $10,000 in the dividend, you’re getting a nice annual payout. That’s solid! But then, with the insider selling, it’s like a double-edged sword. Are they cashing out because they think the stock's peaked? Or are they just rebalancing their portfolios? Nobody really knows for sure.

    Oh, and just a heads-up: JNJ is gearing up for some earnings calls soon. Those can be a big deal, so keep an eye out for how they perform and what they say.

    Alright, that’s the scoop on JNJ today! Just remember, I’m here to share the info, not to give any financial advice. Stay curious, and catch ya later!
    続きを読む 一部表示
    1 分
  • JNJ Today - Aug 08: Insider Selling Hits Stock

    JNJ Today - Aug 08: Insider Selling Hits Stock
    2026/08/08
    Hey there! It's Joey here, your friendly neighborhood investor, breaking down what went down today with Johnson & Johnson. So, JNJ had a bit of a green day, up almost one percent. Not a huge leap, but hey, green's green, right?

    Now, let’s talk about what happened. The stock was buzzing around the same price range most of the day, barely moving until the close. It finished up just a little, which is nice, but there’s definitely a bit of a mixed vibe in the air.

    So, what's the scoop behind the scenes? Well, there’s been some insider selling going on that's got folks raising an eyebrow. The CEO of J&J, Joaquín Duato, sold a whopping $12.5 million worth of his shares. Yeah, that one stung a bit for investors. When the big boss sells off that much stock, it can make people a little jittery. Plus, Rockland Trust Co. sold over 20,000 shares too. That’s a pretty big chunk, so it’s not just one person bailing out.

    On top of that, there’s chatter about whether J&J is fully valued right now, especially with their Darzalex royalties. Some analysts are scratching their heads, wondering if the stock is being priced just right. It’s like when you find a shirt on sale, but you’re not sure if it’s a steal or if it’s just overpriced clearance.

    One quick thing worth knowing: J&J's got some big plans on the horizon with their pharmaceutical pipeline. They’re working on new treatments that could really shake things up. That’s something to keep an eye on as we see how it all unfolds.

    Alright, that’s a wrap for today’s JNJ breakdown! Just remember, this is all about sharing info and having fun with the stock market—no financial advice here. Catch you later!
    続きを読む 一部表示
    2 分
  • JNJ Today - Aug 07: Talc Settlement Proposal Boosts Stock

    JNJ Today - Aug 07: Talc Settlement Proposal Boosts Stock
    2026/08/07
    Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with Johnson & Johnson today. So, JNJ had a pretty chill day, barely moved, but it ended up in the green, up just a tiny bit—like, 0.21%.

    So here’s the scoop. The stock kinda cruised along, but there was some buzz after hours about a big $5.5 billion proposal to settle that whole talc litigation mess. You know, the one that’s been hanging over their heads for a while? Yeah, that one stung. This proposal seems to have given investors a little boost of confidence, which is why we saw a slight uptick.

    As for why the stock didn’t go crazy or anything, I think people are still feeling a bit cautious. Sure, the news about the settlement sounds good, but it’s not like the litigation is totally wiped off the map just yet. Some folks might be holding back until they see how this all plays out.

    Oh, and speaking of things to keep an eye on, there’s some chatter about JNJ’s leadership in innovative medicine. Like, could there be a shift coming? That’s something investors are pondering, and it might just stir the pot a little.

    So, that’s the lowdown on Johnson & Johnson today. Just a little bump after some promising news, but nothing wild. Remember, this is just for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • JNJ Today - Aug 06: Stock Price Target Raised

    JNJ Today - Aug 06: Stock Price Target Raised
    2026/08/06
    Hey there! It’s Joey, your friendly longtime investor, here to break down what went down with Johnson & Johnson today. So, JNJ had a bit of a rough day, dropping almost a percent. Yeah, that one stung a little.

    Now, let's get into the nitty-gritty. JNJ opened strong but then kinda faded away, finishing lower. They had decent volume, so people were definitely paying attention. But it seems like the overall vibes just weren’t that great today.

    So, why the dip? Well, there’s a couple things in the air. Guggenheim raised their price target for JNJ, which is usually a good sign, right? But then you’ve got chatter about the stock potentially being overvalued by about 10%, especially after some leadership changes. That kinda gets folks thinking twice before buying in. Plus, there's this talk about a possible stock sale coming up, which can make investors a bit jittery. It’s like when you hear your favorite artist might be going on a break—you're happy for them, but you’re also like, “Wait, what does this mean for the future?”

    And here's a little nugget for you: even with all this, JNJ's still making waves with new products. People are curious to see how those will pan out, especially since they’re looking at expanding their lineup. So, while today wasn’t their best, there’s still some action happening on the horizon.

    Alright, that’s the scoop for today. Just remember, this is all for fun and info—no financial advice here. Catch you later!
    続きを読む 一部表示
    1 分